---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-23-000029"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:36:05.591448+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics Q1 net loss $37.5M; cash $577M; positive IPF 24-wk data

## Summary
- Q1 net loss $37.5M vs $28.1M YoY; R&D expense $29.3M, G&A $14.2M.
- Cash and short-term investments $577.3M, expected to fund operations into H2 2026.
- INTEGRIS-IPF 320 mg 24-week data: bexotegrast well-tolerated with durable FVC, QLF, and cough improvements.
- Key 2023 milestones: INTEGRIS-PSC 12-wk data Q3; BEACON-IPF Ph2b start mid-2023; Ph1 oncology trial start Q2.
- Closed Jan 2023 public offering raising $269.9M net proceeds.

## SEC filing metadata
- accession: 0001746473-23-000029
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000029/0001746473-23-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000029/plrx-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-23-000029
- JSON: https://secwatch.observer/filing/0001746473-23-000029.json
- Plain text: https://secwatch.observer/filing/0001746473-23-000029.txt

## Key facts
- Earnings Releases
  PLIANT THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: net income Net loss of $37.5 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: Net loss of $37.5 million
  - Result: reported results
  source text: On May 9, 2023, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000029/0001746473-23-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.